|
Message Board >
Beyond Potency: Why Early ADME Screening Matters i
Beyond Potency: Why Early ADME Screening Matters i
Page:
1
Guest
Guest
Oct 19, 2026
11:32 PM
|
A small molecule shows strong activity against a cancer-related target. Follow-up experiments confirm the initial result, and the chemistry team begins developing related compounds. Yet one question remains: can the molecule achieve the exposure needed to make that activity meaningful?
Potency provides only part of the answer. Researchers also need to understand how a compound crosses biological barriers, whether it remains intact in relevant biological environments, and which properties may limit its further development.
For small-molecule oncology programs, permeability testing and plasma stability assessment offer complementary information. Evaluating them within a broader ADME strategy can help teams decide which compounds deserve additional investigation.
Permeability Adds Context to Biological Activity
For a molecule directed at an intracellular target, reaching the relevant cellular compartment is a prerequisite for target engagement. Permeability measurements help characterize one part of that access problem.
Different assays answer different questions. The parallel artificial membrane permeability assay, or PAMPA, examines passive permeation across an artificial membrane. Cell-based models introduce a biological barrier and, depending on the model and experimental design, can help investigate directional transport. These results require interpretation alongside the assay's intended purpose and limitations.
In an oncology discovery program, compound permeability analysis can support the investigation of differences between biochemical and cellular activity. However, a permeability result alone cannot establish intracellular target engagement or predict tumor exposure.
For example, imagine two analogs with similar activity against a purified enzyme but different effects in cells. Permeability becomes one possible explanation to investigate alongside other factors, such as compound stability and the biological context of the cellular assay.
The useful outcome is a more focused follow-up experiment.
Plasma Stability Examines a Different Vulnerability
A compound may cross a membrane effectively yet undergo degradation in plasma. Plasma stability testing investigates whether the parent molecule remains intact during incubation under defined conditions.
An experimental study of high-throughput plasma stability testing demonstrated its usefulness for identifying labile structural features and prioritizing compounds for subsequent studies. The researchers also examined variables affecting assay results, including incubation conditions and plasma batch differences.
A plasma stability assessment therefore addresses a question that permeability testing leaves open: does the compound persist in this biological matrix?
The distinction matters when interpreting an apparently promising profile. Good membrane permeability does not compensate automatically for rapid plasma degradation. Equally, plasma stability does not establish that a compound can reach its intended target.
Study reports should make the experimental context clear, including the plasma species, incubation period, and analytical endpoint. This helps researchers compare compounds without treating measurements from different conditions as interchangeable.
Read the Results Together
Consider a hypothetical series of three oncology compounds.
One analog has strong biochemical potency but weak permeability. A second crosses the assay barrier more readily but loses parent compound rapidly in plasma. A third has slightly weaker potency while performing more consistently across both assessments.
These profiles suggest different questions for the chemistry team. The first may warrant investigation of the properties limiting membrane passage. The second may prompt examination of structural features associated with instability. The third may justify further characterization to determine whether its broader profile supports progression.
This example does not establish a universal ranking. The preferred compound depends on the target, intended route of administration, exposure requirements, and other project-specific evidence.
It does show why a single favorable measurement can be misleading when separated from the rest of the dataset.
Build an ADME Plan Around the Next Decision
Early screening works best when each assay supports a defined development question. Research from NCATS illustrates this approach: solubility, permeability, and microsomal stability are evaluated together within its Tier I ADME screening framework, providing complementary information for compound assessment.
For an oncology team, the next decision might be whether to synthesize additional analogs, investigate an unexpected activity difference, or select compounds for pharmacokinetic studies.
An integrated in vitro ADME evaluation provides a useful framework for organizing those questions. The assay selection should follow the project's needs, with results reviewed together rather than reduced to isolated pass-or-fail labels.
The aim is to identify a compound whose biological activity and disposition properties support the same development goal. Bringing permeability and plasma stability into that discussion early gives researchers a clearer basis for choosing their next experiment.
|
visit website
Guest
Oct 20, 2026
1:19 AM
|
Thank you for creating such a professional and inspiring article-based website; it offers readers both valuable information and an enjoyable reading experience. Do come and visit our website as well we feature a great variety of content that’s both engaging and fun to explore visit website
|
Post a Message
Real Estate Provider #515.000066/Fahim Muhammad Instructor #512.003026/Fahim Muhammad Managing Broker #471.020985 Freedom Financial Institute, IDOI Provider #500026517/NMLS Provider #1405073/Fahim Muhammad NMLS #1851084 All loans originated through Mortgage Loan Direct, NMLS #1192858 15255 South 94th Avenue, Suite 500 Orland Park, IL 60462. Freedom Apex Enterprise & Financial Services Mailing Address: 837 East 162nd Street, Suite 7-8 South Holland, IL 60473 708-704-7309/708-566-1222, 844-49-FREEDOM
FINRA Broker Check
Disclaimer and Release Nothing contained on this website constitutes tax, legal, insurance or investment advice, or the recommendation of or an offer to sell, or the solicitation of an offer to buy or invest in any investment product, vehicle, service or instrument.The information shared is hypothetical and for informational and educational purposes only. Such an offer or solicitation may only be made and discussed by a registered representative of a broker dealer or investment advisor representative of an investment advising firm. You should note that the information and materials are provided "as is" without any express or implied warranties. Past performance is not a guarantee of future results. All investments involve a degree of risk, including a degree of loss. No part of FTAMG’s materials may be reproduced in any form, or referred to in any other publication, without express written permission from FTAMG and or its affiliates. Links to appearances and articles by Fahim Muhammad, The Freedom Coach, whether in the press, on television or otherwise, are provided for informational and educational purposes only and in no way should be considered a recommendation of any particular investment product, vehicle, service or instrument or the rendering of investment advice, which must always be evaluated by a prospective investor in consultation with his or her own financial adviser and in light of his or her own circumstances, including the investor's investment horizon, appetite for risk, and ability to withstand a potential loss of some or all of an investment's value. By using this website, you acknowledge that you have read and understand the foregoing disclaimers and release FTAMG and its affiliates, members, officers, employees and agents from any and all liability whatsoever relating to your use of this site, any such links, or any information contained herein or in any such appearances or articles (whether accessed through such links or downloaded directly from this website). FTAMG highly encourages its viewers and potential clients to obtain the independent advice and services of legal, financial, and tax professionals.
Securities offered through The Leaders Group, Inc. member FINRA/SIPC 475 Springfield Avenue, Suite 1 Summit, NJ 07901 (303) 797-9080
info@freedomfinancialinstitute.orgCopyright© 2025 - Fahim Muhammad Freedom Financial Institute, Inc.
|
|
|
